PPT-Pre-exposure Prophylaxis for HIV Prevention

Efficacy and the importance of adherence Joanne Stekler MD MPH August 20 2015 Key HIV PrEP Trials Using Oral Tenofovir TDF or TenofovirEmtricitabine TDFFTC Study Study Population. Dr.. Rachel Baggaley, HIV dept. WHO, Geneva. GNP+ . WEBINAR: What does PrEP mean for. people living with HIV: science, policy. and . implementation?. . Date: Thursday, 30th July 2015. Time: 4pm CET. Infectious Disease Fellowship Program Director. Associate Professor of Clinical Medicine. University of . Arizona. Cesar Egurrola, Clinical Coordinator. Petersen HIV Clinics. University of Arizona. Special thanks:. cephazolin. 2 g IV . (child: 30 mg/kg up to 2 g) . (IF PROCEDURE MORE THAN 4 hours REDOSE REQUIRED). If MRSA risk factors present or re-operation, . ADD. vancomycin. 15 mg/kg IV . (adult and child). Dr.E.Shojaei. Assistant Prof. of Infectious Diseases. T.U.M.S. Patient factors . Environmental factors . Treatment factors . Ascites . Contaminated medications . Emergency procedure . Chronic inflammation . Katherine Marx, MS, MPH, FNP-BC. June 2014. Disclosure. I, Katherine Marx, have no relevant financial, professional, or personal relationships to disclose.. Objectives. Know current US recommendations for . Settings. Ramona Bhatia, MD. Tuberculosis (TB). Epidemiology. Diagnostics and treatment. Prevention and student health issues . Malaria. Epidemiology. Diagnostics and treatment. Prophylaxis for travelling students. Pre-Exposure Prophylaxis ( PrEP ) for HIV Infection Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health University of California Los Angeles Attending Physician UCLA Center AIDS Research and Education and Ronald Reagan Medical Center Zindoga. Mukandavire. 1. , . Graham F. Medley. 1. , Fern Terris-Prestholt. 1. ,. . Daniel J. Klein. 2. , Anna Bershteyn. 2. , Katharine Kripke. 3. , Joseph Murungu. 4. , . Definate. Nhamo. 4. ,. . 1of 2PageCreated 9/2019ecommendations for Persons Exposed to MeaslesaIG can be administered intramuscularly IGIM or intravenously IGIV Please check references available at https//wwwcdcgov/measles/ind Dr. Anne Pita Lomole. MBCHB, MMED Pediatrics and Child health, . MSc Infectious Disease, DTMH- EA, Asthma Cert NAEP. SA. OUTLINE. Introduction. Epidemiology. Susceptible . infections per . PID. Antibiotic prophylaxis . HIV1 and slower to progress to AIDS.. Most cases are due to type1.. Modes of transmission. 1-sexual.. 2- perinatal.. 3-parenteral(occupational and intravenous drug injection).. 4- blood transfusion.. rapid progressive & highly fatal viral disease of CNS caused by Lyssavirus type 1. .. Zoonotic . disease of warm blooded animals (dogs, cats , bats, racoons, skunks, foxes ) . Transmitted . to man by bite of rabid animal. PrEP. ) Use During Sexual Events by Sexual Minority Men in Canada’s Three Largest Metropolitan Areas. Nathan J. Lachowsky. 1,2,3*. , Cui Z. 3. , . Bacani. N. 3. , Sang JM. 3,4. , Lal A. 3. , Messier-Peet M. Implemented in Public Health Settings in Los Angeles. Jennifer N Sayles, MD, MPH, Gary P García, MPH, Rosemary C Veniegas, PhD, Robert K Bolan, MD, Wilbert C Jordan, MD, and Raphael J Landovitz, MD, MsC.